- Home
- JG vs ACRV Comparison
JG vs ACRV Comparison
Compare JG & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JG
- ACRV
- Stock Information
- Founded
- JG 2012
- ACRV 2018
- Country
- JG China
- ACRV United States
- Employees
- JG N/A
- ACRV N/A
- Industry
- JG Computer Software: Programming Data Processing
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- JG Technology
- ACRV Health Care
- Exchange
- JG Nasdaq
- ACRV Nasdaq
- Market Cap
- JG 48.4M
- ACRV 47.8M
- IPO Year
- JG 2018
- ACRV 2022
- Fundamental
- Price
- JG $8.52
- ACRV $1.89
- Analyst Decision
- JG
- ACRV Buy
- Analyst Count
- JG 0
- ACRV 6
- Target Price
- JG N/A
- ACRV $17.75
- AVG Volume (30 Days)
- JG 11.0K
- ACRV 577.9K
- Earning Date
- JG 11-13-2025
- ACRV 11-12-2025
- Dividend Yield
- JG N/A
- ACRV N/A
- EPS Growth
- JG N/A
- ACRV N/A
- EPS
- JG N/A
- ACRV N/A
- Revenue
- JG $48,999,972.00
- ACRV N/A
- Revenue This Year
- JG $10.90
- ACRV N/A
- Revenue Next Year
- JG N/A
- ACRV $805.34
- P/E Ratio
- JG N/A
- ACRV N/A
- Revenue Growth
- JG 18.82
- ACRV N/A
- 52 Week Low
- JG $4.25
- ACRV $1.05
- 52 Week High
- JG $20.94
- ACRV $8.74
- Technical
- Relative Strength Index (RSI)
- JG 40.59
- ACRV 69.76
- Support Level
- JG $8.02
- ACRV $1.77
- Resistance Level
- JG $9.33
- ACRV $1.99
- Average True Range (ATR)
- JG 0.41
- ACRV 0.12
- MACD
- JG -0.03
- ACRV 0.02
- Stochastic Oscillator
- JG 34.11
- ACRV 84.11
About JG Aurora Mobile Limited
Aurora Mobile Ltd provides stable, and accurate developer services for educational and medical products. It is focused on providing companies with stable and efficient push notification services. It provides a comprehensive suite of services to mobile app developers in mainland China. Through its developer services, it gains access to, aggregate, cleanse, structure and encrypt vast amounts of real-time and anonymous device-level mobile behavioral data. It offers data services such as iAPP which helps the investors to analyze opportunities in the sector, Anti-fraud helps to identify fraud risks, iAudience, iZone and other related services. The company operates and generates its revenue from the People's Republic of China.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.